Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment (NCT07348120) | Clinical Trial Compass
CompletedNot Applicable
Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment
Egypt60 participantsStarted 2025-05-01
Plain-language summary
This is a randomized, double-blind, controlled clinical trial investigating the efficacy and safety of millet seed extract capsules in treating telogen effluvium in female patients. The study will recruit 60 female participants with telogen effluvium who will be randomly assigned to receive either millet seed extract capsules (containing 420 mg millet seed extract, 200 mcg biotin, 6 mg L-cystine, and 27.48 mg vitamin B5) twice daily or Biotin forte capsules (5 mg biotin) once daily for 12 weeks. The primary outcome will measure changes in telogen and anagen hair densities using dermoscopy-assisted phototrichography. Secondary outcomes will assess patient satisfaction and unwanted body hair growth. Safety will be monitored throughout the study period at Cairo University's dermatology clinic.
Who can participate
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Hair shedding degree of 4 or higher according to the Hair Shedding Visual Scale (Sinclair scale).
* Diagnosis of telogen effluvium confirmed by a dermatologist after ruling out other causes of non-scarring alopecia (e.g., alopecia areata, androgenetic alopecia).
* No use of topical or systemic hair loss treatments or oral hair growth supplements for at least 1 month prior to the study.
Exclusion Criteria:
* Pregnancy or breastfeeding.
* History of scalp diseases or conditions affecting hair growth like androgenic alopecia and alopecia areata.
* Use of medications known to cause hair loss.
* Any underlying medical condition that could interfere with the study.
* Use of topical treatment in the last 3 month.
* Use of systemic treatment in the last 3 month such as iron, biotin or any hair growth supplements.
* Annemia or low serum level of ferritin.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Telogen and Anagen Hair Densities measured by Dermoscopy-Assisted Phototrichogram
Timeframe: Baseline (Week 0) and Week 12 of treatment